{"id":"ceftriaxone-clarithromycin","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Hypersensitivity reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins and blocking peptidoglycan cross-linking. Clarithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. Together, they provide synergistic coverage against a wide range of gram-positive and gram-negative bacteria, as well as atypical organisms.","oneSentence":"This combination uses a third-generation cephalosporin antibiotic and a macrolide antibiotic to inhibit bacterial cell wall synthesis and protein synthesis, respectively, providing broad-spectrum antimicrobial coverage.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:44:08.873Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Community-acquired pneumonia"},{"name":"Respiratory tract infections"},{"name":"Other bacterial infections responsive to combination therapy"}]},"trialDetails":[{"nctId":"NCT07485010","phase":"PHASE2","title":"Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial","status":"NOT_YET_RECRUITING","sponsor":"The University of Queensland","startDate":"2027-04","conditions":"Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection, Non-Tuberculous Mycobacterial (NTM) Infections","enrollment":300},{"nctId":"NCT06396078","phase":"PHASE4","title":"Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT)","status":"RECRUITING","sponsor":"Ohio State University","startDate":"2024-07-18","conditions":"Preterm Premature Rupture of Membrane, Pregnancy, High Risk, Preterm Birth","enrollment":56},{"nctId":"NCT06294600","phase":"PHASE3","title":"Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT)","status":"RECRUITING","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2024-02-12","conditions":"Community-acquired Pneumonia","enrollment":330},{"nctId":"NCT07148622","phase":"NA","title":"Effects of Different Antibiotic Regimens in Preterm Premature Rupture of Membranes","status":"COMPLETED","sponsor":"Yuzuncu Yil University","startDate":"2024-10-01","conditions":"Preterm Premature Rupture of Membranes (PPROM), Prophylaxis, Perinatal Outcomes","enrollment":40},{"nctId":"NCT06572761","phase":"PHASE3","title":"A Combination of Antibiotics to Decrease Neonatal Morbidity and Mortality for Previable Threatened Labor","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-09","conditions":"Previable Labour With Intact Membranes","enrollment":350},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT04724044","phase":"PHASE3","title":"Anti-inflammatory Action of Oral Clarithromycin in Community-acquired Pneumonia","status":"COMPLETED","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2021-01-25","conditions":"Community-acquired Pneumonia, Sepsis, Inflammatory Response","enrollment":278},{"nctId":"NCT05417997","phase":"PHASE3","title":"Effect of Kunamin in SARS-CoV-2 RT-PCR Positive Covid-19 Patients","status":"COMPLETED","sponsor":"RAAS Nutritionals, LLC","startDate":"2021-05-29","conditions":"COVID-19 Respiratory Infection, FLU, Cold; Influenza","enrollment":71},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT00621504","phase":"PHASE3","title":"Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2008-01","conditions":"Bacterial Pneumonia","enrollment":606},{"nctId":"NCT01207739","phase":"PHASE4","title":"Persistent Lyme Empiric Antibiotic Study Europe","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2010-09","conditions":"Lyme Disease, Borrelia Infection","enrollment":280},{"nctId":"NCT00717561","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of IV/PO Moxifloxacin in Subjects With Community-acquired Pneumonia","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-02","conditions":"Pneumonia","enrollment":60},{"nctId":"NCT01602874","phase":"PHASE3","title":"Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2011-01","conditions":"Community Acquired Bacterial Pneumonia, Complicated Intra-Abdominal Infection","enrollment":""},{"nctId":"NCT00914888","phase":"PHASE3","title":"Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia","status":"WITHDRAWN","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2011-01","conditions":"Community Acquired Bacterial Pneumonia, Complicated Intra-Abdominal Infection","enrollment":""},{"nctId":"NCT00034736","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Levofloxacin in the Treatment of Children With Community-acquired Pneumonia in the Hospital or Outpatient Setting","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2002-08","conditions":"Pneumonia","enrollment":691}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ceftriaxone/ Clarithromycin","genericName":"Ceftriaxone/ Clarithromycin","companyName":"RAAS Nutritionals, LLC","companyId":"raas-nutritionals-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ceftriaxone is a small molecule inhibitor of bacterial penicillin-binding protein, classified as an INHIBITOR. It is used to treat conditions such as osteomyelitis, community-acquired pneumonia, and sepsis, and can be administered orally or intravenously.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}